ChinaXiv Reports Clinical Remission of a Critically Ill COVID-19 Patient Treated by Human Umbilical Cord Mesenchymal Stem Cells
The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies.
ChinaXiv has performed a recent study that has proven significant improvement of a critically ill COVID-19 patient that was treated with the transfer of human umbilical cord mesenchymal stem cells. Celltex is continuing to monitor and participate in this effective research.
If you currently have your MSCs banked at Celltex and are wondering what options are available to you, please contact the Client Services team today by completing the form on our Request a Consultation page, by calling (713) 590-1000 or sending an email to firstname.lastname@example.org. If you are not a client but would like to bank your MSCs, please complete our online client assessment and a Client Services Coordinator will contact you.
More Recent News
Legendary Football Coach and Celltex Sports Program Manager Inducted to Pitt Athletics Hall of Fame 2020 ClassRead More
Bedridden child matures into a healthy mother of two thanks to stem cells
Sarah spent most of her life in a hospital bed until Celltex used her own stem cells to heal her body. She’s doing better than anyone ever imagined, and now she’s helping others who are desperate for medical help.Read More